Cargando…

A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review

OBJECTIVES: In 2015, the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program proposed shifting the therapeutic focus on ulcerative colitis (UC) toward altering the natural history of the disease course by regularly monitoring objective measurements of disease activity and ta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ungaro, Ryan, Colombel, Jean-Frédéric, Lissoos, Trevor, Peyrin-Biroulet, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553548/ https://www.ncbi.nlm.nih.gov/pubmed/30908297 http://dx.doi.org/10.14309/ajg.0000000000000183

Ejemplares similares

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
por: Magro, Fernando, et al.
Publicado: (2023)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Early Intervention in Ulcerative Colitis: Ready for Prime Time?
por: Solitano, Virginia, et al.
Publicado: (2020)

Is Hartmann’s Pouch an Option in the Management of Acute Severe Ulcerative Colitis?
por: Renaud, Myriam, et al.
Publicado: (2022)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis
por: Parkes, Gareth, et al.
Publicado: (2023)

Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States
por: Patel, Haridarshan, et al.
Publicado: (2017)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
por: Napolitano, Maria, et al.
Publicado: (2022)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View
por: Dubinsky, Marla C, et al.
Publicado: (2021)

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2021)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications
por: Agrawal, Manasi, et al.
Publicado: (2020)

Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention
por: Colombel, Jean-Frédéric
Publicado: (2018)

Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study
por: Allocca, Mariangela, et al.
Publicado: (2018)

Methionine synthase A2756G polymorphism may predict ulcerative colitis and methylenetetrahydrofolate reductase C677T pancolitis, in Central China
por: Chen, Min, et al.
Publicado: (2008)

Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
por: Lichtenstein, Gary R., et al.
Publicado: (2023)

Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation
por: Allocca, Mariangela, et al.
Publicado: (2021)

LIAISON(®) Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study
por: Fiorino, Gionata, et al.
Publicado: (2022)

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
por: Colombel, J.‐F., et al.
Publicado: (2016)

Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey
por: Odufalu, Florence-Damilola, et al.
Publicado: (2023)

Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study
por: Allocca, Mariangela, et al.
Publicado: (2022)

Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study
por: Bessissow, Talat, et al.
Publicado: (2022)

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial
por: Dotan, Iris, et al.
Publicado: (2023)

iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

A186 ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
por: Clemow, D B, et al.
Publicado: (2023)

Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe
por: Ruiz-Casas, Leonardo, et al.
Publicado: (2021)

Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme
por: Schreiber, Stefan, et al.
Publicado: (2023)

Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis
por: Bencardino, Sarah, et al.
Publicado: (2023)

Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Correction to: The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe
por: Ruiz-Casas, Leonardo, et al.
Publicado: (2021)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial
por: Schreiber, Stefan, et al.
Publicado: (2023)

Protein-Losing Enteropathy in Ulcerative Colitis
por: Ungaro, Ryan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4up1trn6b2ip116tcm442d2kv8